ClearPoint Neuro reported weak second-quarter results, especially in drug delivery disposables, and delays in preclinical service ramp-up have lowered 2026 expectations. However, recent regulatory clarity from the FDA increases the likelihood of a revenue boost in 2027/2028 as the AMT-130 treatment is commercialized. Investors should be patient due to growing dilution risks, but the stock is expected to perform well over the next 12 to 18 months.
ClearPoint Neuro announced its Q2 2026 financial results with $10.9 million in revenue, up 18% year-over-year, driven by growth in neurosurgery navigation and therapy sales. The company is expanding its neuro drug delivery platform, including a new p...
Aspen Neuroscience received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, its investigational autologous cell therapy for Parkinson's disease. This designation allows for expedited development and review, inclu...
